Back to Research Home
NVONovo Nordisk A/S
Health Care · Biotechnology: Pharmaceutical Preparations · Mega
$39.05−0.96%
As of 23 Oct 2026Mkt cap $207B
Stage 13
AVOID
Fundamentals
52.0/75
Technical
5.0/15
Independent
57.0/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- +1.1%
- 3M
- −21.4%
- 6M
- −5.1%
- 1Y
- −26.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 37.2%
- Operating margin
- 44.2%
- FCF margin
- 19.1%
- Current ratio
- 0.8x
Growth
- Revenue growth
- +11.1%Latest FY YoY
- Revenue CAGR
- +20.3%
- EPS CAGR
- +20.6%
- FCF CAGR
- +3.7%
Capital
- Share-count trend
- −0.5%3Y annualised
- Net debt
- $17.8B1.0x OCF
Annual trend
- CAGR 2021–2025
- +20.3%
- Latest · 2025
- $47B
- YoY
- +11.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- WATCH · CURRENT
Key takeaway
Adjusted Q2 sales and operating profit improved, Wegovy pill adoption and broader GLP-1 access support demand, and the obesity pipeline remains strong; however, intense Lilly competition and still-muted 2026 growth guidance keep the thesis under active watch rather than establishing a replacement case.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded